source
- City Therapeutics raises $200M in IPO to fund thromboembolic disease pipelineCity Therapeutics, an RNA interference biotech focused on thromboembolic diseases, completed an initial public offering that raised $200 million. The company sold about 11 million shares at $18 ea…
- FDA reviews interim access policy for compounded peptides as Enspryng label expandsThe U.S. Department of Health and Human Services and the Food and Drug Administration have drafted a new interim access policy that would allow compounding pharmacies to use certain peptide drugs u…